2014
DOI: 10.1182/blood.v124.21.5472.5472
|View full text |Cite
|
Sign up to set email alerts
|

Clinical Pharmacokinetic (PK) and Safety (Immunogenicity) of Rituximab Biosimilar RTXM83 in Combination with Chemotherapy CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL)

Abstract: Background: RTXM83 is a rituximab biosimilar candidate manufactured by MAbxience Company. Full spectrum of physicochemical and preclinical studies showed biosimilarity of RTXM83 and originator drug MabThera®/Rituxan® marketed by Roche. MabThera®/Rituxan® product is approved to treat Non-Hodgkin´s Lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis in the EU and US, plus it is approved to treat Diffuse Large B-cell lymphoma (DLBCL) in the EU. Rituximab is also used for other types of lymphoma (e.g. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
4
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 0 publications
1
4
0
Order By: Relevance
“…26 In addition, a prospective study with limited comparability due to the selection of patients with a good prognosis is reported, 27 and several small studies have been carried out investigating the use of rituximab biosimilars licensed outside of the EU in DLBCL, including China, India, and Turkey. [28][29][30][31] In REFLECT, R-CHOP therapy achieved similar results for PFS rate (78.5%) and ORR (94.7%, according to best overall response) to those reported in other studies, although CR results differ from study to study as shown in Table 5. This difference in CR rate may be partially explained by variation in study design and patient population.…”
Section: Discussionsupporting
confidence: 69%
See 1 more Smart Citation
“…26 In addition, a prospective study with limited comparability due to the selection of patients with a good prognosis is reported, 27 and several small studies have been carried out investigating the use of rituximab biosimilars licensed outside of the EU in DLBCL, including China, India, and Turkey. [28][29][30][31] In REFLECT, R-CHOP therapy achieved similar results for PFS rate (78.5%) and ORR (94.7%, according to best overall response) to those reported in other studies, although CR results differ from study to study as shown in Table 5. This difference in CR rate may be partially explained by variation in study design and patient population.…”
Section: Discussionsupporting
confidence: 69%
“… 26 In addition, a prospective study with limited comparability due to the selection of patients with a good prognosis is reported, 27 and several small studies have been carried out investigating the use of rituximab biosimilars licensed outside of the EU in DLBCL, including China, India, and Turkey. 28 31 …”
Section: Discussionmentioning
confidence: 99%
“…The results were consistent with the study conducted by Florez et al in which none of the patients of the DLBCL treated with rituximab showed immunogenicity. [13] However, in a developmental study of rituximab conducted by Roche Drugs Limited in patients with low-grade or follicular NHL, anti-human anti-chimeric antibody was detected in 4 out of 356 (1.1%). [2] Thus, the available data suggest that immunogenic potential of the test drug was comparable to the reference drug DLBCL patients and is also consistent to the previously conducted studies with the similar molecule.…”
Section: Discussionmentioning
confidence: 99%
“…Pfizer ORR LTBFL Preclinical: PF-05280586 showed similar structural and in vitro functional characteristics and similar in vivo PK and immunogenicity profiles to rituximab [43] Phase I: PF-05280586 showed similar PK, effectiveness, and safety to rituximab in subjects with active rheumatoid arthritis [44] CT-P10 Celtrion ORR FL Phase III: CT-P10 showed equivalent PK and similar efficacy (ACR20/ 50/70), PD, safety [45], and immunogenicity [46] to rituximab in subjects with rheumatoid arthritis RTXM83 mAbxience ORR DLBCL Preclinical: RTXM83 showed similar structural and in vitro functional characteristics and similar in vivo PK/PD profiles to rituximab [47] Phase III: RTXM83 showed comparable PK and safety profile (immunogenicity) to rituximab when combined with CHOP for firstline treatment of DLBCL [48] ABP…”
Section: Indolent Nhlmentioning
confidence: 99%